Australia markets open in 46 minutes
  • ALL ORDS

    7,562.50
    -37.40 (-0.49%)
     
  • AUD/USD

    0.7145
    +0.0017 (+0.24%)
     
  • ASX 200

    7,239.80
    -39.50 (-0.54%)
     
  • OIL

    70.06
    +1.91 (+2.80%)
     
  • GOLD

    1,782.90
    -2.60 (-0.15%)
     
  • BTC-AUD

    81,715.04
    +2,190.15 (+2.75%)
     
  • CMC Crypto 200

    1,460.81
    +31.88 (+2.23%)
     

Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RADNOR, Pa., October 26, 2021--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the third quarter ended September 30, 2021 before the market opens on November 9, 2021. The company will host a conference call at 8:30 a.m. Eastern Time on November 9, 2021, to provide a business update and discuss the financial results.

Tuesday, November 9, 8:30 a.m. ET

Domestic: +1 833-979-2765
International: (343) 761-2590
Webcast Link: https://event.on24.com/wcc/r/3435370/D4A161A628859FC2957F63CBDDD69D3A
Conference ID: 6362837

About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year, is planning to conduct a Phase 3 trial in tuberous sclerosis complex, and a Phase 3 trial in refractory status epilepticus is ongoing. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005173/en/

Contacts

Sasha Damouni Ellis
Vice President, Corporate Affairs & Investor Relations
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting